首页> 美国卫生研究院文献>Personality Neuroscience >Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders
【2h】

Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders

机译:氯胺酮和神经质:内在性障碍的双重假设

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Psychiatric disorders can often be viewed as extremes of personality traits. The primary action of drugs that ameliorate these disorders may, thus, be to alter the patient’s position on a relevant trait dimension. Here, we suggest that interactions between such trait dimensions may also be important for disorder. Internalizing disorders show important differences in terms of range of activity and speed of response of medications. Established antidepressant and anxiolytic medications are slow in onset and have differing effects across different internalizing disorders. In contrast, low-dose ketamine is rapidly effective and improves symptom ratings in all internalizing disorders. To account for this, we propose a “double hit” model for internalizing disorders: generation (and maintenance) require two distinct forms of neural dysfunction to coincide. One hit, sensitive to ketamine, is disorder-general: dysfunction of a neural system linked to high levels of the personality trait of neuroticism. The other hit is disorder-specific: dysfunction of one of a set of disorder-specific neural modules, each with its own particular pattern of sensitivity to conventional drugs. Our hypothesis applies only to internalizing disorders. So, we predict that ketamine will be effective in simple phobia and (perhaps partially) in anorexia nervosa, but would make no such prediction about other disorders where neuroticism might also be important secondarily (e.g. attention deficit hyperactivity disorder and schizophrenia).
机译:精神疾病通常可以被视为人格特质的极端。因此,改善这些疾病的药物的主要作用可能是改变患者在相关性状维度上的位置。在这里,我们建议这些特征维度之间的相互作用对于失调也可能很重要。内在化疾病在活性范围和药物反应速度方面显示出重要差异。既定的抗抑郁药和抗焦虑药起效缓慢,并且在不同的内在化疾病中具有不同的作用。相反,小剂量氯胺酮迅速有效,并改善了所有内在化疾病的症状等级。为了解决这个问题,我们提出了一种“双重打击”模型来处理内部疾病:产生(和维持)需要两种不同形式的神经功能障碍相吻合。对氯胺酮敏感的一种疾病是一般性疾病:神经系统功能障碍与神经质人格特征的高水平相关。另一个打击是特定于疾病的:一组特定于疾病的神经模块之一的功能障碍,每个模块都有其对常规药物敏感性的特殊模式。我们的假设仅适用于内部疾病。因此,我们预测氯胺酮在简单恐惧症和(可能是部分)对神经性厌食症中将是有效的,但对神经质可能次要重要的其他疾病(例如注意缺陷多动症和精神分裂症)则没有这样的预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号